Latest Publications

Featured Article

European Journal of Cancer. July 2019

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy

Collin K. Chin | Sara Hall | Celia Green | Guy Van Hazel | Dominic Spagnolo | Chan Yoon Cheah

Link to online journal article

---

This paper highlights a case of haemophagocytic lymphohistiocytosis (HLH), a rare but important complication of checkpoint inhibitor (CI) therapy which are widely used in the treatment of solid organ and haematological malignancies. We present a case report, diagnostic work-up, associated challenges in management and review the existing literature regarding HLH secondary to CI therapy. Our findings suggest that treatment discontinuation and high-dose corticosteroid therapy without chemotherapy may be sufficient in treating HLH related to CI therapy.

More Publications

• Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls.
  Source: Dr Chan CheahPublished on 2019-05-30
• Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
  Source: Dr Chan CheahPublished on 2019-05-29
• The Benefit of Physical Activity in Adolescent and Young Adult Cancer Patients During and After Treatment: A Systematic Review.
  Source: Dr David JoskePublished on 2019-05-16
• Management of patients with follicular lymphoma treated first line with obinutuzumab.
  Source: Dr Chan CheahPublished on 2019-05-07
• Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
  Source: Dr Chan CheahPublished on 2019-05-01
• A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.
  Source: Dr Chan CheahPublished on 2019-04-16
• PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice.
  Source: Dr Carolyn GrovePublished on 2019-03-31
• Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
  Source: Dr Chan CheahPublished on 2019-03-01
• The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
  Source: Dr David JoskePublished on 2019-01-12
• Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
  Source: Dr Gavin CullPublished on 2019-01-12
• Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
  Source: Dr Chan CheahPublished on 2019-01-09
• ‘It is a journey of discovery’: living with myeloma.
  Source: Dr Bradley AugustsonPublished on 2018-10-29
• ‘It is a journey of discovery’: living with myeloma.
  Source: Dr David JoskePublished on 2018-10-29
• Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
  Source: Dr Gavin CullPublished on 2018-09-27
• Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder.
  Source: Dr Julie CrawfordPublished on 2018-09-21

Older posts